Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Rating) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 526,600 shares, a decrease of 17.4% from the May 15th total of 637,500 shares. Based on an average daily volume of 164,900 shares, the days-to-cover ratio is currently 3.2 days. Approximately 8.3% of the company’s stock are sold short.
NASDAQ:LUCD traded down $0.06 during midday trading on Thursday, reaching $1.74. The stock had a trading volume of 2,306 shares, compared to its average volume of 166,624. Lucid Diagnostics has a 1-year low of $1.74 and a 1-year high of $13.52. The firm’s fifty day simple moving average is $2.18 and its 200-day simple moving average is $3.55.
Lucid Diagnostics (NASDAQ:LUCD – Get Rating) last posted its earnings results on Monday, March 28th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.12). As a group, analysts anticipate that Lucid Diagnostics will post -1.42 EPS for the current fiscal year.
Several research analysts have recently commented on the stock. Canaccord Genuity Group dropped their price target on shares of Lucid Diagnostics from $18.00 to $12.00 and set a “buy” rating on the stock in a research note on Tuesday, March 29th. BTIG Research restated a “buy” rating and set a $5.00 price target on shares of Lucid Diagnostics in a research note on Friday, May 13th. Canaccord Genuity Group dropped their price target on shares of Lucid Diagnostics from $12.00 to $8.00 in a research note on Thursday, May 12th. Ascendiant Capital Markets dropped their price target on shares of Lucid Diagnostics to $13.00 in a research note on Thursday, June 9th. Finally, Needham & Company LLC dropped their price target on shares of Lucid Diagnostics from $13.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, March 29th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $12.00.
About Lucid Diagnostics (Get Rating)
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
- Get a free copy of the StockNews.com research report on Lucid Diagnostics (LUCD)
- The Q2 Earnings Season Could Be A Bloodbath
- Commercial Metals Company Is Ready To Rebound
- The Institutions Turn The Tide For Jabil
- A10 Networks: Key 5G Infrastructure Stock that’s Beating the Market
- Allstate: A Safe Stock During Volatile Times, Which Will Benefit From Rising Rates
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.